HUGO FRY

Managing Director | Vice President, Sanofi UK | ABPI

Hugo Fry is the Managing Director of Sanofi UK, the 6th largest pharmaceutical company in the UK. He is also Vice-President of the Association of the British Pharmaceutical Industry (ABPI).

Prior to becoming Managing Director of Sanofi UK, Hugo was the Chief Marketing Officer for Sanofi Pasteur MSD (SPMSD), leading the commercial effort for the European vaccine joint venture. Hugo has held global strategic positions and commercial operational roles, leading vertically integrated teams from Drug Discovery through Clinical Development, Regulatory Affairs, Market Access, Industrial Affairs, Medical Affairs and Commercialisation.

After nine years with Servier, Hugo joined Aventis UK in 2003 as Head of Commercial Excellence. From 2007, Hugo spent four years in Russia leading Sanofi’s Diabetes, Oncology, Cardiovascular, Internal Medicine and Consumer Healthcare businesses, where he was also responsible for the acquisition and set-up of an insulin manufacturing facility. Following a strategic acquisition, he was then appointed General Manager of Zentiva Russia, where he was instrumental in maintaining Zentiva as one of the fastest growing companies in Russia while integrating into the Sanofi Group. Hugo then joined the Sanofi Diabetes Leadership Team as Global Project Leader, based across France, Germany and the USA, heading R&D, Industrial affairs and commercial operations before assuming his role at SPMSD.

Hugo holds a B.Sc. in Chemistry from the University of Salford and studied Finance at London Business School.